UNSPSC 51384531: Naproxen etemesil

This classification denotes a cyclooxygenase inhibitor C17H20O5S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 214269U36R, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, 2-(methylsulfonyl)ethyl ester, (.alpha.s)-, but more generally known as naproxen etemesil, which bears US NIH Compound Identifier 25170420. Most nations, for tariff and trade purposes, schedule naproxen etemesil under HS 29189900 and SITC 51396. As of Q4 2014, NAPROXEN ETEMESIL remains US FDA's Preferred Term for this commodity.

SMILES: C[C@@H](C1CCC2CC(CCC2C1)OC)C(=O)OCCS(=O)(=O)C.

UNSPSC 51384531 Naproxen etemesil is a Commodity code that, based on recent state and local procurement activity, does not align with what is actually being solicited under this taxonomy entry. The single recent opportunity posted under this code—Seminole County, Florida's IFB 60459723LAS—solicits naloxone and drug deactivation systems for community health support, not naproxen etemesil, a nonsteroidal anti-inflammatory drug. The mismatch suggests either a data classification error or a one-time misapplication of the code to a procurement outside its intended scope. State and local governments typically use UNSPSC pharmaceutical codes to classify specific branded or generic medications when purchasing through health departments, county medical suppliers, or community health programs, but the recent activity under this particular code does not reflect that pattern.

Seminole County's procurement represents the only recent opportunity in the available data. The county issued an IFB on June 30, 2026 (with a response deadline of July 26, 2023, suggesting a data entry inconsistency in the source) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The contract carries an initial two-year term with a one-year renewal option and requires vendors to meet federal compliance standards, including E-Verify and drug-free workplace certification. The procurement does not specify set-aside designations. The mismatch between the code's nominal scope and the actual procurement makes this code a low-priority target for firms seeking to pursue state and local pharmaceutical opportunities; the code does not show reliable recent activity aligned with naproxen etemesil procurement.